Provided is a local hemostasis material, which exerts little influence on the human body, is inexpensive, and exerts a good hemostatic. The local hemostasis material comprises a base material having a first major surface and a layer including cationized cellulose on the first major surface, wherein the layer including cationized cellulose has a thickness of no less than 6.7 .Math.m.

Adhesives comprising rubber, tackifier, oil, and optionally absorbent and active ingredient are described. The adhesives are suitable for medical applications as they are repositionable on skin. Also described are medical articles using the adhesives.

Adhesives comprising rubber, tackifier, oil, and optionally absorbent and active ingredient are described. The adhesives are suitable for medical applications as they are repositionable on skin. Also described are medical articles using the adhesives.

A composite hydrogel contains alginate hydrogel and acellular matrix hydrogel. The ingredients used to produce the acellular matrix hydrogel contains acellular matrix and transglutaminases (TGases). The alginate hydrogel contains salginate complex. The alginate hydrogel and acellular matrix hydrogel constitute a three-dimensional crosslinking structure. The TGases can catalyze isopeptide bonding between acellular matrixes, and thus forms acellular matrix hydrogel through crosslinking.

A composite hydrogel contains alginate hydrogel and acellular matrix hydrogel. The ingredients used to produce the acellular matrix hydrogel contains acellular matrix and transglutaminases (TGases). The alginate hydrogel contains salginate complex. The alginate hydrogel and acellular matrix hydrogel constitute a three-dimensional crosslinking structure. The TGases can catalyze isopeptide bonding between acellular matrixes, and thus forms acellular matrix hydrogel through crosslinking.

The present invention is directed to a hemostatic patch comprising a porous substrate and at least a pair of co-reactive polymer reagents comprising at least one nucleophilic polyalkylene oxide based component and at least one electrophilic polyalkylene oxide-based on the porous substrate in a molar ratio of about 0.2 to about 0.9:1 of primary nucleophilic groups in excess to available electrophilic groups. The present invention is also directed to processes for the manufacture and use of such hemostatic patches.

The present invention is directed to a hemostatic patch comprising a porous substrate and at least a pair of co-reactive polymer reagents comprising at least one nucleophilic polyalkylene oxide based component and at least one electrophilic polyalkylene oxide-based on the porous substrate in a molar ratio of about 0.2 to about 0.9:1 of primary nucleophilic groups in excess to available electrophilic groups. The present invention is also directed to processes for the manufacture and use of such hemostatic patches.

The present technology provides a composition comprising a mixture of a source of calcium ions, alginate conjugated to an acrylate monomer (ALG-A), carboxymethylcellulose conjugated to an acrylate monomer (CMC-A) and water, wherein the mixture is a shear-thinning gel. The compositions may further include a polythiol agent. Such compositions are injectable due to their shear-thinning properties, yet stay in place, undergo in situ crosslinking, and provide safe, simple and efficacious endovascular embolization. Methods of making and using such compositions are also provided.

The present invention relates to a multi-use hemostatic composition and a method for producing the same, and more particularly, to a technique relating to a multi-use a hemostatic agent in which a first component having a modified anionized substituent and a second component that is a polymer having adhesiveness are included to provide improved hemostatic ability and biocompatibility so as to have applicability into surgery, laparoscopy, and various surgical procedures.

The present disclosure pertains to therapeutic hydrogels that comprise an anionic polysaccharide crosslinked by a branched polyamine, wherein the branched polyamine comprises at least two primary amine groups, more typically at least three primary amine groups. The present disclosure also pertains to medical compositions that comprise such therapeutic hydrogels and to methods of medical treatment in which such therapeutic hydrogels are delivered to a patient in need of medical treatment.